News | April 28, 2026
Essilor Stellest lens positioned as key breakthrough in myopia control in India
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
nSEPIA aims to bring structure to an area long dominated by subjectivity
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
